Premium
Influence of methylenetetrahydrofolate reductase polymorphisms in oral cancer patients
Author(s) -
Sailasree R.,
Nalinakumari K.R.,
Sebastian P.,
Kannan S.
Publication year - 2011
Publication title -
journal of oral pathology and medicine
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.887
H-Index - 83
eISSN - 1600-0714
pISSN - 0904-2512
DOI - 10.1111/j.1600-0714.2010.00943.x
Subject(s) - methylenetetrahydrofolate reductase , medicine , cancer , reductase , genetics , oncology , genotype , biology , enzyme , gene , biochemistry
J Oral Pathol Med (2011) 40 : 61–66 Background: Methylenetetrahydrofolate reductase (MTHFR) is a key enzyme in folate metabolism. Two common polymorphisms associated with MTHFR gene – C677T and A1298C – influence the thermolabile nature and activity of the enzyme. This study aimed to investigate the role of MTHFR polymorphisms on oral cancer susceptibility and its potential impact on the prognostic outcome. Methods: Oral cancer cases and controls were genotyped using PCR‐RFLP technique for MTHFR C677T and A1298C polymorphisms. Disease susceptibility analysed using regression analysis. The association between clinical outcomes and the polymorphisms were analysed using univariate and multivariate model. Results: The 677CT+TT genotype showed a significant three‐fold reduction in oral cancer risk (RR‐0.35, p‐0.009). 1298CC genotype showed decreased cancer risk when compared to AA+AC genotype (RR‐0.55, p‐0.062). When prognostic significance of MTHFR polymorphism was evaluated, 677CT+TT patients showed improved survival than the CC individuals (RR = 0.56, P = 0.378). The 1298 CC and AC+CC showed an increased risk for treatment failure and poor survival when compared with the wild AA genotype (HR = 4.27, P = 0.001). Conclusion: Here we observed MTHFR C677T to influence oral cancer susceptibility, while A1298C polymorphism associated with patient prognosis. Our data support MTHFR polymorphism to be an independent prognostic marker in oral carcinoma.